Raptor Pharma Up As Leerink Likes Huntington’s Drug

By | July 16, 2015

Scalper1 News

Rare-disease specialist Raptor Pharmaceutical (RPTP) was up 7% in early trading Thursday after Leerink lifted its price target on hopes for upcoming drug data. Analyst Joseph Schwartz affirmed his outperform rating and lifted his target to 20 from 15, citing a data readout in the third quarter on a clinical trial of Huntington’s disease drug RP103. Schwartz assigned a 60% probability of the drug ultimately getting to market, though he split the Scalper1 News

Scalper1 News